Abstract:Background Compound mutations of TNNT2R141W/+ (encoding troponin T) and MYPNS1296T/+ (encoding myopalladin) are associated with familial left ventricle non-compaction cardiomyopathy (LVNC). However, it remains unclear in which would be the pathogenic mutation, the underlying mechanism, and the target therapy for LVNC. Methods Knock-in C57BL/6J mice harboring mutations in orthologous genes in Tnnt2R154W or/and MypnS1291T and human cardiomyocytes derived from iPSC of healthy donors and LVNC patients (LVNC-hCM) were employed for disease modeling, omics analysis, mechanistic study, and drug development. Results Using knock-in mice for disease modeling, it was clarified that the orthologous mutation in Tnnt2, but not in Mypn, led to cardiac hypertrabeculation, noncompaction, and heart failure. 3D protein structure modeling by Swiss-model found a loss of slat bridge between TNNT2(R141W) and E-257 in tropomyosin, contributing to the decreased cardiac contraction. Further mechanistic study discovered that troponin T (TNNT2) appears to function as an HDAC1 sponge in cardiomyocyte nuclei. The compromised association between nuclear TNNT2(R141W) and HDAC1 causes cardiac epigenetic perturbation and subsequentially leads to transcriptional dysregulation. The downregulation of cardiac muscular genes was concomitant with the impairment of cardiac contraction, which would be partially rescued by pan HDAC inhibitor. Besides, the upregulation of TGFβ-signaling molecules and EZH2 did contribute to cardiac growth defects, which were mitigated by TGFβR1 inhibitor (A83-01) and EZH2 inhibitor (GSK503), respectively. Simvastatin, a hit drug identified from the repurposed drug screening, can restore nuclear TNNT2(R141W)-HDAC1 association, thereby recovering cardiac epigenetic, translational profiles, growth and function in LVNC-hCM in vitro and cardiac function in LVNC mice harboring Tnnt2R154W in vivo. The cardiac function was significantly improved in the proband receiving 5 mg once daily for consecutive two years. Conclusion Mutant TNNT2(R141W) diminished its nuclear HDAC1 sponge function in cardiomyocyte to induce LVNC pathogenesis through perturbating cardiac epigenetic and the gene expressions. Targeting to HDAC, TGFβ, EZH2 may rescue part of cardiac pathological signaling. Simvastatin can act as a chemical chaperone to comprehensively recover cardiac epigenetic via restoring nuclear TNNT2(R141W)-HDAC1 association.

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility

Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Danicamtiv Increases Myosin Recruitment and Alters Cross-Bridge Cycling in Cardiac Muscle

1-Deoxynojirimycin Promotes Cardiac Function and Rescues Mitochondrial Cristae in Mitochondrial Hypertrophic Cardiomyopathy.

Danicamtiv reduces myosin's working stroke but enhances contraction by activating the thin filament

Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function

Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases

Drug discovery for heart failure targeting myosin-binding protein C

Small molecule-mediated refolding and activation of myosin motor function

Mechanisms of a novel regulatory light chain-dependent cardiac myosin inhibitor

Neutraceuticals silybin B, resveratrol and epigallocatechin-3 gallate (EGCG) bind to troponin to restore the loss of lusitropy caused by cardiomyopathy mutations in vitro, in vivo, and in silico

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Activating Cardiac Myosin, a Novel Inotropic Mechanism to Improve Cardiac Function in Conscious Dogs with Congestive Heart Failure

Discovery of small molecule guanylyl cyclase B receptor positive allosteric modulators

Mitochondrial Creatine Kinase Attenuates Pathologic Remodeling in Heart Failure.

Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review

Discovery of Potent and Selective 2-(Benzylthio)pyrimidine-based DCN1-UBC12 Inhibitors for Anticardiac Fibrotic Effects

Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction

Abstract P439: Harnessing Multiscale Models Of A Dilated Cardiomyopathy Mutation For Precision Medicine

Targeting mutant TNNT2-induced epigenetic perturbation and pathogenic signaling in left ventricular non-compaction cardiomyopathy